DUXAP8 and invasive breast carcinoma: Specifically, patients with high DUXAP8 expression levels had a shorter survival time than patients with low DUXAP8 expression levels in breast invasive carcinoma (BRCA) (p = 0.041), colon adenocarcinoma (COAD) (p = 0.0094), HNSC (p = 0.047), KIRC (p = 7.6e−6), kidney renal papillary cell carcinoma (KIRP) (p = 0.0057), LIHC (P = 0.0038), and UCEC (p = 0.03) (Figure 2).